Key result
In a patient with severe hypertriglyceridemia and markedly reduced plasma apoC-II, no rare causative variants were detected in the APOC2 gene despite decreased transcription of apoC-II mRNA.
Case Report (n=1)
A case of apoC-II deficiency without causative mutations in the APOC2 gene implies that other genes may regulate apoC-II levels.
Case of hypoapoC-II-like deficiency without APOC2 variants cautions against assuming coding mutations; leaves open non-APOC2 mechanisms in hypertriglyceridemia.
AIM: Familial apolipoprotein C-II (apoC-II) deficiency is a rare autosomal recessive disorder with marked hypertriglyceridemia resulting from impaired activation of lipoprotein lipase. In most cases of apoC-II deficiency, causative mutations have been found in the protein-coding region of APOC2; however, several atypical cases of apoC-II deficiency were reported to have markedly reduced, but detectable levels of plasma apoC-II protein (hereafter referred to as hypoapoC-II), which resulted from decreased promoter activity or improper splicing of apoC-II mRNA due to homozygous mutations in APOC2. Here we aim to dissect the molecular bases of a new case of hypoapoC-II. METHODS: We performed detailed biochemical/genetic analyses of our new case of hypoapoC-II, manifesting severe hypertriglyceridemia (plasma triglycerides, 3235 mg·dL(-1)) with markedly reduced levels of plasma apoC-II (0.6 mg·dL(-1)). RESULTS: We took advantage of a monocyte/macrophage culture system to prove that transcription of apoC-II mRNA was decreased in the patient's cells, which is compatible with the reported features of hypoapoC-II. Concomitantly, transcriptional activity of the minigene reporter construct of the patient's APOC2 gene was decreased; however, no rare variant was detected in the patient's APOC2 gene. Fifty single nucleotide variants were detected in the patient's APOC2, but all were common variants (allele frequencies >35%) that are supposedly not causative. CONCLUSIONS: A case of apoC-II deficiency was found that is phenotypically identical to hypoapoC-II but with no causative mutations in APOC2, implying that other genes regulate apoC-II levels. The clinical entity of hypoapoC-II is discussed.
No takes yet. Share an insight, caveat, or question.
Takase et al. (2013) conducted a case report in Apolipoprotein C-II deficiency (hypoapoC-II) (n=1). Genetic and biochemical analysis of APOC2 gene was evaluated on Identification of causative mutations in the APOC2 gene. In a patient with severe hypertriglyceridemia and markedly reduced plasma apoC-II, no rare causative variants were detected in the APOC2 gene despite decreased transcription of apoC-II mRNA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: